Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Cancer Research|March 13, 2002
Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell culturesWilliam R Wilson, Susan M Pullen, Alison Hogg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2011
The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxiaJingli Wang, Annika Foehrenbacher, Jiechuang Su, et al.
Frontiers in Pharmacology|October 4, 2018
Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell CulturesCho R Hong, Gib Bogle, Jingli Wang, et al.
Plos Computational Biology|October 26, 2018
An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroidsXinjian Mao, Sarah McManaway, Jagdish K Jaiswal, et al.
Radiation Research|May 26, 2007
Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustardsWilliam R Wilson, Kevin O Hicks, Susan M Pullen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2007
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamineKevin O Hicks, Hilary Myint, Adam V Patterson, et al.
Journal of Medicinal Chemistry|February 18, 2005
Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer culturesFrederik B Pruijn, Joanna R Sturman, H D Sarath Liyanage, et al.
Frontiers in Oncology|October 11, 2013
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104Annika Foehrenbacher, Kashyap Patel, Maria R Abbattista, et al.
Cancer Chemotherapy and Pharmacology|August 5, 2010
A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicityKashyap Patel, Steve S F Choy, Kevin O Hicks, et al.
Journal of Medicinal Chemistry|November 16, 2007
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transportMichael P Hay, Kevin O Hicks, Frederik B Pruijn, et al.
Pageof 4